Credit: Sanford Burnham Prebys
LA JOLLA, CALIF. – April 20, 2021 Scientists at Sanford Burnham Prebys have identified, at an atomic level, how a part of a protein called PLEKHA7 interacts with a cell’s membrane to regulate important intercellular communications. The research, published in the journal Structure, points to hotspots within PLEKHA7 as targets for drugs. These targets could be key in designing treatments for advanced colon, breast and ovarian cancers.
The region, or domain, in PLEKHA7 that the researchers examined, pleckstrin homology (PH), is commonly found in proteins that regulate the movement of cells as well as other important cellular activities. If the interaction between the PH domain and the lipids that comprise cell membranes is disrupted, diseases such as cancer can occur.
“PH domains have been studied for some time but examining their interactions with membrane-associated lipids has been challenging,” says Francesca M. Marassi, Ph.D., professor and director of the Cell and Molecular Biology of Cancer Program at Sanford Burnham Prebys and corresponding author of the study. “We optimized our structural investigations by using an artificial membrane disc several nanometers in size. This nanodisc is a ‘substitute’ cell membrane and has been an important tool in overcoming obstacles in studying structural aspects of fatty interfaces, such as those involving lipids.”
The investigators used several techniques to detail the precise areas where the PH domain interacted with lipids in a cell’s membrane. Each of the three techniques was equally important: X-ray crystallography provided a snapshot of the structure; magnetic resonance showed the precise association of the PH domain with the lipid membrane surface; and computer simulations put all of this information together to generate a dynamic movie of the interaction.
“We were able to determine that the PH domain interacts with the cellular membrane at several locations simultaneously, thereby demonstrating the key role of the membrane as a platform for directing cell signaling and adhesion,” says Marassi. “We found at least three sites along the PH domain that are engaged in binding lipids. Having multiple sites is crucial, because if you think of the PH binding sites as a zipper between proteins and lipids, each additional notch engaged by a zipper makes the binding stronger and more resistant to being pulled apart.”
One of the reasons the scientists were interested in exploring PLEKHA7 was that the protein has recently been identified as a potential anti-cancer target. However, its molecular mechanism of action has been uncertain. Additionally, the researchers were interested in the PH domain because it has been implicated in advanced breast, renal and ovarian cancers and, most prominently, plays an important role in colorectal cancer.
“Clinicians have shown that PLEKHA7 is elevated in patients with colorectal cancer, and its levels increase as the disease worsens. It has also been shown that inhibiting PLEKHA7 decreases cellular proliferation and migration,” says Marassi. “Therefore, the PLEKHA7 PH domain might be a useful drug target, but more work is needed to develop agents with greater potency and optimized pharmacological properties.”
As a next step, the scientists hope to share their structural images with colleagues in other labs at Sanford Burnham Prebys, and elsewhere, to screen for drugs that target the PH domain and lipid membrane binding sites.
Additional study authors include Alexander E. Aleshin, Yong Yao, Andrey A. Bobkov, Jinghua Yu, Gregory Cadwell, Michael G. Klein, Laurie A. Bankston, Robert C. Liddington and Garth Powis of Sanford Burnham Prebys as well as Amer Iftikhar, Chuqiao Dong and Wonpil Im from the Departments of Biological Sciences, Chemistry and Bioengineering at Lehigh University, PA.
The study’s DOI is: 10.1016/j.str.2021.03.018.
Research reported in this press release was supported by grants from the National Institutes of Health (GM118186, CA179087, CA160398, CA030199) and the National Science Foundation (MCB1810695).
Garth Powis is director of PHusis Therapeutics. The authors declare no other potential competing interests.
Related Journal Article